AVITA Medical (ASX: AVH) secured a new contract manufacturing agreement and amended its existing distribution agreement for its biosynthetic wound matrix product PermeaDerm, for the treatment of wounds, with Stedical Scientific, according to a Tuesday filing with the Australian bourse.
Under the manufacturing agreement, effective Monday, the company will produce PermeaDerm at its Ventura, California facility, while the amended distribution deal revises revenue-sharing terms with Stedical, the filing said.
AVITA will retain 60% of sales, with Stedical receiving 40% after manufacturing costs. The agreement also sets performance milestones and extends the contract term, the filing added.
Shares of the company rose 7% in recent Tuesday trade.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。